Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026

Human medicines European public assessment report (EPAR): Aujemflu, Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture), Status: Opinion

Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR): Hopledo, levodopa,carbidopa, Status: Opinion

Human medicines European public assessment report (EPAR): Nylaspeg, pegfilgrastim, Status: Opinion

Human medicines European public assessment report (EPAR): Onswik, Insulin efsitora alfa, Status: Opinion

Human medicines European public assessment report (EPAR): Tacquell, Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded, Status: Opinion

Human medicines European public assessment report (EPAR): Yartemlea, Narsoplimab, Status: Opinion

Human medicines European public assessment report (EPAR): Xervyteg, Allogeneic faecal microbiota, pooled, Status: Opinion

Summary of opinion: Leqvio, 25/06/2026 Positive